| Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection RM Lynch, E Boritz, EE Coates, A DeZure, P Madden, P Costner, ... Science translational medicine 7 (319), 319ra206-319ra206, 2015 | 468 | 2015 |
| A recombinant vesicular stomatitis virus Ebola vaccine JA Regules, JH Beigel, KM Paolino, J Voell, AR Castellano, Z Hu, ... New England Journal of Medicine 376 (4), 330-341, 2017 | 452 | 2017 |
| Chimpanzee adenovirus vector Ebola vaccine JE Ledgerwood, AD DeZure, DA Stanley, EE Coates, L Novik, ME Enama, ... New England Journal of Medicine 376 (10), 928-938, 2017 | 362 | 2017 |
| Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials MR Gaudinski, KV Houser, KM Morabito, Z Hu, G Yamshchikov, ... The Lancet 391 (10120), 552-562, 2018 | 312 | 2018 |
| Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial LJ Chang, KA Dowd, FH Mendoza, JG Saunders, S Sitar, SH Plummer, ... The Lancet 384 (9959), 2046-2052, 2014 | 306 | 2014 |
| Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults Clinical & Experimental Immunology 182 (3), 289-301, 2015 | 275 | 2015 |
| A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus–associated cryoglobulinemic vasculitis MC Sneller, Z Hu, CA Langford Arthritis & Rheumatism 64 (3), 835-842, 2012 | 273 | 2012 |
| A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults JE Ledgerwood, P Costner, N Desai, L Holman, ME Enama, ... Vaccine 29 (2), 304-313, 2010 | 255 | 2010 |
| Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults MR Gaudinski, EE Coates, KV Houser, GL Chen, G Yamshchikov, ... PLoS medicine 15 (1), e1002493, 2018 | 216 | 2018 |
| DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials JE Ledgerwood, CJ Wei, Z Hu, IJ Gordon, ME Enama, CS Hendel, ... The Lancet infectious diseases 11 (12), 916-924, 2011 | 213 | 2011 |
| HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells M Catalfamo, M Di Mascio, Z Hu, S Srinivasula, V Thaker, J Adelsberger, ... Proceedings of the National Academy of Sciences 105 (50), 19851-19856, 2008 | 183 | 2008 |
| Immune regulation by glucocorticoids can be linked to cell type–dependent transcriptional responses LM Franco, M Gadkari, KN Howe, J Sun, L Kardava, P Kumar, S Kumari, ... Journal of Experimental Medicine 216 (2), 384-406, 2019 | 162 | 2019 |
| Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised … H Kibuuka, NM Berkowitz, M Millard, ME Enama, A Tindikahwa, ... The Lancet 385 (9977), 1545-1554, 2015 | 153 | 2015 |
| Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial UN Sarwar, P Costner, ME Enama, N Berkowitz, Z Hu, CS Hendel, S Sitar, ... The Journal of infectious diseases 211 (4), 549-557, 2015 | 151 | 2015 |
| A monoclonal antibody for malaria prevention MR Gaudinski, NM Berkowitz, AH Idris, EE Coates, LSA Holman, ... New England Journal of Medicine 385 (9), 803-814, 2021 | 139 | 2021 |
| Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect JE Ledgerwood, K Zephir, Z Hu, CJ Wei, LJ Chang, ME Enama, ... The Journal of infectious diseases 208 (3), 418-422, 2013 | 138 | 2013 |
| A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques P Zhang, E Narayanan, Q Liu, Y Tsybovsky, K Boswell, S Ding, Z Hu, ... Nature medicine 27 (12), 2234-2245, 2021 | 109 | 2021 |
| Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria RL Wu, AH Idris, NM Berkowitz, M Happe, MR Gaudinski, C Buettner, ... New England Journal of Medicine 387 (5), 397-407, 2022 | 85 | 2022 |
| Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial MR Gaudinski, KV Houser, NA Doria-Rose, GL Chen, RSS Rothwell, ... The Lancet HIV 6 (10), e667-e679, 2019 | 85 | 2019 |
| Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans JE Ledgerwood, Z Hu, IJ Gordon, G Yamshchikov, ME Enama, S Plummer, ... Clinical and Vaccine Immunology 19 (11), 1792-1797, 2012 | 82 | 2012 |
